BG108425A - Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor - Google Patents

Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor

Info

Publication number: BG108425A
Authority: BG; Bulgaria
Prior art keywords: pyridines; pyrimidines; releasing factor; corticotropin releasing; substituted pyrazinones
Prior art date: 2001-05-14

Application number

BG108425A

Other languages

Bulgarian (bg)

English (en)

Inventor

Argyrios Arvanitis

Paul Gilligan

Richard Hartz

Original Assignee

Bristol-Myers Squibb Pharma Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-14

Filing date

2003-12-08

Publication date

2004-12-30

2003-12-08 Application filed by Bristol-Myers Squibb Pharma Company filed Critical Bristol-Myers Squibb Pharma Company

2004-12-30 Publication of BG108425A publication Critical patent/BG108425A/xx

Links

HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical class OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 title abstract 2
150000003222 pyridines Chemical class 0.000 title abstract 2
150000003230 pyrimidines Chemical class 0.000 title abstract 2
102000012289 Corticotropin-Releasing Hormone Human genes 0.000 title 1
108010022152 Corticotropin-Releasing Hormone Proteins 0.000 title 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 title 1
208000017194 Affective disease Diseases 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 abstract 1
208000019022 Mood disease Diseases 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Addiction (AREA)
Immunology (AREA)
Hematology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Molecular Biology (AREA)
Child & Adolescent Psychology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Dermatology (AREA)

BG108425A 2001-05-14 2003-12-08 Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor BG108425A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US29070601P	2001-05-14	2001-05-14

Publications (1)

Publication Number	Publication Date
BG108425A true BG108425A (en)	2004-12-30

Family

ID=23117196

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108425A BG108425A (en)	2001-05-14	2003-12-08	Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor

Country Status (22)

Country	Link
US (2)	US7205306B2 (is)
EP (1)	EP1392309B1 (is)
JP (1)	JP2004533447A (is)
KR (1)	KR20030094410A (is)
CN (1)	CN1527710A (is)
BG (1)	BG108425A (is)
BR (1)	BR0209575A (is)
CA (1)	CA2446980A1 (is)
CZ (1)	CZ20033053A3 (is)
DE (1)	DE60217669D1 (is)
EE (1)	EE200300546A (is)
HU (1)	HUP0304048A2 (is)
IL (1)	IL158669A0 (is)
IS (1)	IS7017A (is)
MX (1)	MXPA03010324A (is)
NO (1)	NO20035055D0 (is)
PL (1)	PL366577A1 (is)
RU (1)	RU2003135424A (is)
SK (1)	SK13752003A3 (is)
WO (1)	WO2002092090A1 (is)
YU (1)	YU90503A (is)
ZA (1)	ZA200308729B (is)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA05012087A (es) *	2003-05-09	2006-02-22	Pharmacia & Upjohn Co Llc	Nuevas pirazinonas como antagonistas del receptor crf1.
JP2007512275A (ja)	2003-11-24	2007-05-17	エフ．ホフマン−ラ　ロシュ　アーゲー	ピラゾリルおよびイミダゾリルピリミジン
CA2569887A1 (en)	2004-06-09	2005-12-22	Glaxo Group Limited	Pyrrolopyridine derivatives
GB0420722D0 (en) *	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
HN2005000795A (es) *	2004-10-15	2010-08-19	Aventis Pharma Inc	Pirimidinas como antagonistas del receptor de prostaglandina d2
US20060161001A1 (en) *	2004-12-20	2006-07-20	Amgen Inc.	Substituted heterocyclic compounds and methods of use
GT200600005A (es) *	2005-01-12	2006-08-16		Un derivado de 2-(aminocarbonilo ciclico)-indolina y una composicion farmaceutica que lo contiene
TW200640881A (en) *	2005-02-15	2006-12-01	Du Pont	Fungicidal pyrazine derivatives
TWI417095B (zh)	2006-03-15	2013-12-01	Janssen Pharmaceuticals Inc	１，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
MX2008015648A (es) *	2006-06-21	2009-01-09	Du Pont	Pirazinonas como inhibidores de proliferacion celular.
EP2121654A1 (en) *	2007-01-10	2009-11-25	Albany Molecular Research, Inc.	5-pyridinone substituted indazoles
WO2008107398A2 (en) *	2007-03-02	2008-09-12	Basf Se	Pyrazine compounds
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) *	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
KR20100044225A (ko) *	2007-07-21	2010-04-29	알바니 몰레큘라 리써치, 인크.	5-피리디논 치환된 인다졸
US8252937B2 (en)	2007-09-14	2012-08-28	Janssen Pharmaceuticals, Inc.	1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
US8722894B2 (en)	2007-09-14	2014-05-13	Janssen Pharmaceuticals, Inc.	1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
PL2203439T3 (pl)	2007-09-14	2011-06-30	Addex Pharmaceuticals Sa	1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony
RU2492170C9 (ru)	2007-11-14	2013-12-27	Орто-Макнейл-Янссен Фармасьютикалз, Инк.	Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
HRP20130992T1 (hr) *	2008-04-29	2013-11-22	Merck Patent Gmbh	Derivati arilpirazinona kao stimulatori luäśenja inzulina, postupci za njihovo dobivanje i njihova uporaba za lijeäśenje dijabetesa
CN102105149A (zh) *	2008-07-31	2011-06-22	百时美施贵宝公司	作为促肾上腺皮质激素释放因子受体活性调节剂的取代的氨基甲酸酯衍生物
JP5547194B2 (ja)	2008-09-02	2014-07-09	ジャンセンファーマシューティカルズ，インコーポレイテッド．	代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
RU2517181C2 (ru)	2008-10-16	2014-05-27	Орто-Макнейл-Янссен Фармасьютикалз, Инк.	Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
WO2010060589A1 (en)	2008-11-28	2010-06-03	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
CN102439008B (zh)	2009-05-12	2015-04-29	杨森制药有限公司	1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
MY153912A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
PL2649069T3 (pl)	2010-11-08	2016-01-29	Janssen Pharmaceuticals Inc	Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
EP2661435B1 (en)	2010-11-08	2015-08-19	Janssen Pharmaceuticals, Inc.	1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103261195B (zh)	2010-11-08	2015-09-02	杨森制药公司	1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CN102786512A (zh) *	2012-05-31	2012-11-21	中国人民解放军军事医学科学院毒物药物研究所	N-芳基不饱和稠环叔胺类化合物及其制备方法和抗肿瘤应用
US20140206667A1 (en)	2012-11-14	2014-07-24	Michela Gallagher	Methods and compositions for treating schizophrenia
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
HUE053734T2 (hu)	2014-01-21	2021-07-28	Janssen Pharmaceutica Nv	2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
KR20220049612A (ko)	2014-01-21	2022-04-21	얀센 파마슈티카 엔.브이.	대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
CN119613318B (zh) *	2024-11-29	2026-04-14	滁州市庆云医药有限公司	一种西洛多辛中间体及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0008864A1 (en) *	1978-08-15	1980-03-19	FISONS plc	Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
IE63502B1 (en) *	1989-04-21	1995-05-03	Zeneca Ltd	Aminopyrimidine derivatives useful for treating cardiovascular disorders
DE4029648A1 (de) *	1990-09-19	1992-03-26	Hoechst Ag	4-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
US5395817A (en) *	1992-01-22	1995-03-07	Imperial Chemical Industries Plc	N-arylindoles and their use as herbicides
FR2694004B1 (fr) *	1992-07-21	1994-08-26	Adir	Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
ATE177101T1 (de) *	1992-12-17	1999-03-15	Pfizer	Pyrrolopyrimidine als crf antagonisten
RU2153494C2 (ru)	1993-10-12	2000-07-27	Дзе Дюпон Мерк Фармасьютикал Компани	1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция
EP0901476A4 (en)	1996-03-26	2001-08-16	Du Pont Pharm Co	PYRIDINES AND PYRIMIDINES FUSION ARYLOXY AND ARYLTHIO AND DERIVATIVES THEREOF
US6107300A (en)	1996-03-27	2000-08-22	Dupont Pharmaceuticals	Arylamino fused pyrimidines
TW440563B (en) *	1996-05-23	2001-06-16	Hoffmann La Roche	Aryl pyrimidine derivatives and a pharmaceutical composition thereof
WO1997044308A1 (en)	1996-05-24	1997-11-27	The Dow Chemical Company	Process for preparing aliphatic ester compounds and alkanols
HU228962B1 (en)	1996-07-24	2013-07-29	Bristol Myers Squibb Pharma Co	Azolo triazines, pharmaceutical compositions containing them and use of the compounds
US6159980A (en)	1996-09-16	2000-12-12	Dupont Pharmaceuticals Company	Pyrazinones and triazinones and their derivatives thereof
WO1999001439A1 (en)	1997-07-03	1999-01-14	Du Pont Pharmaceuticals Company	Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
PL337888A1 (en)	1997-07-03	2000-09-11	Du Pont Pharm Co	Imidazoprimidines and imidazopyridines for use in treating neurological disorders
EP1012151B1 (en)	1997-09-02	2002-08-07	Bristol-Myers Squibb Pharma Company	Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
WO1999051608A1 (en)	1998-04-03	1999-10-14	Du Pont Pharmaceuticals Company	THIAZOLO[4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS
US6124463A (en)	1998-07-02	2000-09-26	Dupont Pharmaceuticals	Benzimidazoles as corticotropin release factor antagonists
CA2339188A1 (en)	1998-08-21	2000-03-02	Dupont Pharmaceuticals Company	Isoxazolo¬4,5-d\|pyrimidines as crf antagonists

2002
- 2002-05-14 CA CA002446980A patent/CA2446980A1/en not_active Abandoned
- 2002-05-14 CN CNA028140907A patent/CN1527710A/zh active Pending
- 2002-05-14 RU RU2003135424/04A patent/RU2003135424A/ru not_active Application Discontinuation
- 2002-05-14 IL IL15866902A patent/IL158669A0/xx unknown
- 2002-05-14 CZ CZ20033053A patent/CZ20033053A3/cs unknown
- 2002-05-14 BR BR0209575-0A patent/BR0209575A/pt not_active IP Right Cessation
- 2002-05-14 KR KR10-2003-7014755A patent/KR20030094410A/ko not_active Withdrawn
- 2002-05-14 PL PL02366577A patent/PL366577A1/xx unknown
- 2002-05-14 EE EEP200300546A patent/EE200300546A/xx unknown
- 2002-05-14 MX MXPA03010324A patent/MXPA03010324A/es unknown
- 2002-05-14 EP EP02729225A patent/EP1392309B1/en not_active Expired - Lifetime
- 2002-05-14 JP JP2002589007A patent/JP2004533447A/ja active Pending
- 2002-05-14 WO PCT/US2002/015493 patent/WO2002092090A1/en not_active Ceased
- 2002-05-14 DE DE60217669T patent/DE60217669D1/de not_active Expired - Lifetime
- 2002-05-14 SK SK1375-2003A patent/SK13752003A3/sk unknown
- 2002-05-14 US US10/145,440 patent/US7205306B2/en not_active Expired - Lifetime
- 2002-05-14 HU HU0304048A patent/HUP0304048A2/hu unknown
- 2002-05-14 YU YU90503A patent/YU90503A/sh unknown
2003
- 2003-11-07 IS IS7017A patent/IS7017A/is unknown
- 2003-11-10 ZA ZA200308729A patent/ZA200308729B/en unknown
- 2003-11-13 NO NO20035055A patent/NO20035055D0/no not_active Application Discontinuation
- 2003-12-08 BG BG108425A patent/BG108425A/xx unknown
2007
- 2007-02-14 US US11/675,012 patent/US7319100B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
IS7017A (is)	2003-11-07
EP1392309A1 (en)	2004-03-03
KR20030094410A (ko)	2003-12-11
CZ20033053A3 (en)	2004-05-12
IL158669A0 (en)	2004-05-12
WO2002092090A1 (en)	2002-11-21
CA2446980A1 (en)	2002-11-21
RU2003135424A (ru)	2005-05-20
US7319100B2 (en)	2008-01-15
PL366577A1 (en)	2005-02-07
HUP0304048A2 (hu)	2004-04-28
ZA200308729B (en)	2005-02-10
US7205306B2 (en)	2007-04-17
DE60217669D1 (de)	2007-03-08
US20030171380A1 (en)	2003-09-11
NO20035055D0 (no)	2003-11-13
MXPA03010324A (es)	2004-02-17
CN1527710A (zh)	2004-09-08
HK1059220A1 (en)	2004-06-25
EP1392309B1 (en)	2007-01-17
YU90503A (sh)	2006-03-03
EP1392309A4 (en)	2006-01-18
EE200300546A (et)	2004-04-15
US20070155740A1 (en)	2007-07-05
SK13752003A3 (en)	2004-11-03
BR0209575A (pt)	2004-04-20
JP2004533447A (ja)	2004-11-04

Publication	Publication Date	Title
BG108425A (en)	2004-12-30	Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor
DK0901374T3 (da)	2004-04-05	Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser
DE69807085D1 (de)	2002-09-12	Heterocyclyl-substituierte annellierte pyridine und pyrimidine als antagonisten des corticotropin freisetzenden hormons (crh), verwendbar für die behandlung von cns und stress
CY1109069T1 (el)	2014-07-02	Ενωσεις ιμιδαζοπυριδαζινης
LV12262A (lv)	1999-04-20	Ar arilaminu kondenseti piridini un pirimidini
TW200503705A (en)	2005-02-01	3-amino chroman and 2-amino tetralin derivatives
MXJL05000010A (es)	2005-06-07	Compuestos de fenil-aza-benzimidazol para modular la ige e inhibir la proliferacion celular.
TW200602058A (en)	2006-01-16	Fused pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives
NO952398D0 (no)	1995-06-16	Pyrrolpyrimidiner som CRF antagonister
GB0209891D0 (en)	2002-06-05	Novel compounds
UA92503C2 (ru)	2010-11-10	Соединения 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенного пиридина для лечения неврологических, психиатрических или болевых расстройств
MXJL05000009A (es)	2005-06-07	Compuestos de fenilindon para modular la ige e inhibir la proliferacion celular.
SG157231A1 (en)	2009-12-29	Substituted p-diaminobenzene derivatives
MXPA03010269A (es)	2004-05-05	Derivados de 2,5-disubstituida piridina, pirimidina, piridazina y 1,2,4-triazina para usarse como inhibidores de p38.
ATE296809T1 (de)	2005-06-15	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
YU71503A (sh)	2006-05-25	4-(2-butilamino)-2,7-dimetil-8-(2-metil-6-metoksipirid-3-il) pirazolo/1,5-a/-1,3,5-triazin,njegovi enantiomeri i farmaceutski prihvatljive soli kao ligandi receptora za faktor koji oslobađa kortikotropin
BG104992A (en)	2001-11-30	2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n- (6-morpholine-4-yl-4-o-tolyl-pyridine-3-yl)- isobutyramide
MX2007015427A (es)	2008-04-16	Inhibidores de azinona y diazinona v3 para depresion y trastornos de estres.
WO2004092144A3 (en)	2005-03-24	Quinazoline compounds useful as p38 kinase inhibitors
DE602005010821D1 (de)	2008-12-18	Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
ATE281439T1 (de)	2004-11-15	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
MXPA05010975A (es)	2005-11-28	Derivados de (6-(fenoxi)-pirido[3,4-d]pirimidin-2-il)-amina como inhibidores de p38 cinasa para el tratamiento de condiciones inflamatorias como artritis reumatoide.
WO2003005969A3 (en)	2003-12-04	Tetrahydropurinones as corticotropin releasing factor
AU2002251788A1 (en)	2002-08-12	Novel compounds and uses thereof
MXPA04007026A (es)	2004-10-11	Pirimidinonas y pirimidintionas sustituidas.